Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Chen, Ping ^a   Zhu, Jiang ^b   Liu, Ding Yi ^a   Li, Hui Yan ^c   Xu, Nie ^d   Hou, Mei ^b  

^a Chengdu Cancer Hospital   (China)

^b SICHUAN UNIVERSITY   (China)

^c HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^d CHENGDU FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Clinical pathological factors; Prognosis; Small cell lung cancer; Survivin; VEGF

Indexed keywords

SURVIVIN; VASCULOTROPIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; CARCINOGENESIS; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SMALL CELL LUNG CARCINOMA;

ADULT; AGED; CARCINOGENESIS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SMALL CELL LUNG CARCINOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MLCS; MLOWN;

EID: 84890258864     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0775-5     Document Type: Review

References (28)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
2. Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer. 2000;28:173-85. (Pubitemid 30254226)
3. Batus M, Myint R, Coon J, Basu S, Kaiser K, Fidler M, Bonomi P. N-cadherin, E-cadherin, ERCC1, and c-kit expression in small cell lung cancer (SCLC) and potential for new therapeutic targets. J Clin Oncol. 2009; 27(Suppl 15s):(abstract e22157).
4. Cañadas I, Arumi M, Lema L, Martinez A, Grande E, Bellosillo B, Rojo F, Rovira A, Albanell J, Arriola E. MET in small cell lung carcinoma (SCLC): effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in patients. J Clin Oncol. 2009; 27 (Suppl 15s):(abstract e14617).
5. Gonzalez R, Silva JM, Sanchez A, Dominguez G, Garcia JM, Chen XQ, Stroun M, Provencio M, España P, Anker P, Bonilla F. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann Oncol. 2000;11:1097-104.
6. Srinivasula SM, Ashwell JD. IAPs: what's in a name? Mol Cell. 2008;30:123-35. (Pubitemid 351626688)
7. Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10:188-93.
8. Adamkov M, Halasova E, Kajo K, Machalekova K, Vybohova D, Varga I, Rajcany J. Survivin: a promising biomarker in breast carcinoma. Neoplasma. 2010;57:572-7.
9. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood. 2011;118:2191-9.
10. Wang M, Liu BG, Yang ZY, Hong X, Chen GY. Significance of survivin expression: prognostic value and survival in stage III non-small cell lung cancer. Exp Ther Med. 2012;3:983-8.
11. Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR, Sun TT, Altieri DC. A survivin gene signature predicts aggressive tumor behavior. Cancer Res. 2005;65:3531-4. (Pubitemid 40616325)
12. Trabulo S, Cardoso AM, Santos-Ferreira T, Cardoso AL, Simões S, Pedroso de Lima MC. Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents. Mol Pharm. 2011;8:1120-31.
13. Nassar A, Lawson D, Cotsonis G, Cohen C. Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome. Appl Immunohistochem Mol Morphol. 2008;16:113-20.
14. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91:2026-32. (Pubitemid 32476366)
15. Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer. 2004;46:11-9. (Pubitemid 39201379)
16. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9:777-94. (Pubitemid 43116546)
17. Lizasa T, Chang H, Suzuki M, Otsuji M, Yokoi S, Chiyo M, Motohashi S, Yasufuku K, Sekine Y, Iyoda A, Shibuya K, Hiroshima K, Fujisawa T. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res. 2004;10:5361-6. (Pubitemid 39100472)
18. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58-61. (Pubitemid 19115892)
19. Giatromanolaki A, Sivridis E, Koukourakis MI. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol. 2006;29:408-17. (Pubitemid 44197549)
20. Pavlyukov MS, Antipova NV, Balashova MV, Vinogradova TV, Kopantzev EP, Shakhparonov MI. Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem. 2011;286:23296-307.
21. Kim K, Chie EK, Wu HG, Kim SG, Lee SH, Kang GH, Hyun CL, Ha SW. High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis. 2011;26:1019-23.
22. Yang Y, Zhu J, Gou HF, Cao D, Jiang M, Hou M. Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC). Med Oncol. 2011;28:796-803.
23. Zhu HX, Wang QF, Hu CF, Zhang WC, Quan LP, Liu M, Xu NZ, Xiao ZF. High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumor Biol. 2011;32:1147-53.
24. Yasumitsu A, Tabata C, Tabata R, Hirayama N. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol. 2010;5:479-83.
25. Oshita F, Ito H, Ikehara M, Ohgane N, Hamanaka N, Nakayama H, Saito H, Yamada K, Noda K, Mitsuda A, Kameda Y. Prognostic impact of surviving, cyclin D1, integrin beta 1, and VEGF in patients with small adenocarcinoma of stage I lung cancer. Am J Clin Oncol. 2004;27:425-8. (Pubitemid 39045257)
26. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006;17:597-604.
27. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS, Altieri DC. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol. 2000;156:393-8. (Pubitemid 30643793)
28. Beierle EA, Nagaram A, Dai W, Iyengar M, Chen MK. VEGF-mediated survivin expression in neuroblastoma cells. J Surg Res. 2005;127:21-8. (Pubitemid 40814626)